Bank of America
INMB icon

Bank of America’s INmune Bio INMB Stock Holding History

Bank of America’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Buy
25,502
+6,961
+38% +$9.92K ﹤0.01% 5637
2025
Q4 		$28.9K Buy
18,541
+8,354
+82% +$14.9K ﹤0.01% 5973
2025
Q3 		$21.1K Sell
10,187
-1,986
-16% -$4.55K ﹤0.01% 7056
2025
Q2 		$28.1K Sell
12,173
-18,220
-60% -$134K ﹤0.01% 6983
2025
Q1 		$237K Sell
30,393
-56
-0.2% -$445 ﹤0.01% 6081
2024
Q4 		$142K Buy
30,449
+4,015
+15% +$20.9K ﹤0.01% 6259
2024
Q3 		$142K Buy
26,434
+14,668
+125% +$104K ﹤0.01% 6182
2024
Q2 		$104K Buy
11,766
+2,998
+34% +$29.6K ﹤0.01% 6241
2024
Q1 		$103K Sell
8,768
-5,343
-38% -$64.6K ﹤0.01% 6224
2023
Q4 		$159K Buy
14,111
+9,640
+216% +$80.8K ﹤0.01% 6195
2023
Q3 		$30.3K Hold
4,471
– – ﹤0.01% 6627
2023
Q2 		$40.6K Sell
4,471
-246
-5% -$1.98K ﹤0.01% 6525
2023
Q1 		$30.5K Buy
4,717
+2,846
+152% +$22.9K ﹤0.01% 6638
2022
Q4 		$11.9K Buy
1,871
+13
+0.7% +$92 ﹤0.01% 6879
2022
Q3 		$12K Hold
1,858
– – ﹤0.01% 7188
2022
Q2 		$16K Sell
1,858
-1,700
-48% -$12.7K ﹤0.01% 7246
2022
Q1 		$30K Sell
3,558
-211
-6% -$1.9K ﹤0.01% 7374
2021
Q4 		$38K Buy
3,769
+1,970
+110% +$29.2K ﹤0.01% 7319
2021
Q3 		$35K Buy
1,799
+99
+6% +$1.91K ﹤0.01% 7200
2021
Q2 		$30K Hold
1,700
– – ﹤0.01% 7019
2021
Q1 		$20K Hold
1,700
– – ﹤0.01% 6886
2020
Q4 		$29K Sell
1,700
-1,000
-37% -$9.42K ﹤0.01% 6498
2020
Q3 		$28K Buy
2,700
+987
+58% +$10K ﹤0.01% 6209
2020
Q2 		$9K Buy
1,713
+13
+0.8% +$65 ﹤0.01% 6467
2020
Q1 		$6K Sell
1,700
-3
-0.2% -$14 ﹤0.01% 6469
2019
Q4 		$10K Buy
1,703
+3
+0.2% +$14 ﹤0.01% 6644
2019
Q3 		$10K Buy
1,700
+898
+112% +$6.65K ﹤0.01% 6722
2019
Q2 		$8K Buy
+802
New +$8.12K ﹤0.01% 6763

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America's INMB Position: Q1 2026 in Review

Bank of America increased its INmune Bio (INMB) stake by 38% in Q1 2026, buying an estimated $9.92K and bringing the position to 25,502 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5637.

Bank of America first reported a position in INMB in Q2 2019 and has held it in 28 quarters since. The position peaked at $237K in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Bank of America held 25,502 shares of INmune Bio worth $28.8K as of Q1 2026.
  • Bank of America bought 6,961 INmune Bio shares in Q1 2026, an estimated $9.92K.
  • INmune Bio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5637 holding.
  • Bank of America first reported a position in INmune Bio in Q2 2019 and has held it in 28 quarters since.
  • Bank of America's INmune Bio position peaked at $237K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.